 Connection
Michael Mitchell to Immunotherapy, Adoptive
This is a "connection" page, showing publications Michael Mitchell has written about Immunotherapy, Adoptive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.389 |
|
|
|
-
Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horiz. 2026 Jan 05; 11(1):22-36.
Score: 0.718
-
Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, Mai D, Figueroa-Espada CG, Thatte AS, Haley RM, Mukalel AJ, Hamilton AG, Alameh MG, Weissman D, Sheppard NC, June CH, Mitchell MJ. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Adv Mater. 2024 06; 36(26):e2313226.
Score: 0.633
-
Atsavapranee ES, Billingsley MM, Mitchell MJ. Delivery technologies for T cell gene editing: Applications in cancer immunotherapy. EBioMedicine. 2021 May; 67:103354.
Score: 0.518
-
Xiao Y, Bai M, Ang MJY, Mitchell MJ, Han X. Transient T cell therapies. Adv Pharmacol. 2026; 106:179-212.
Score: 0.184
-
Kim D, Moon SJ, Han EL, Feng E, Murray AM, Wang J, Liu W, Kong G, June CH, Mitchell MJ. HITE: HIV Inspired Lipid Nanoparticle Platform for CAR T Cell Engineering. Nano Lett. 2026 May 06; 26(17):5668-5679.
Score: 0.183
-
Gong N, Han X, Xue L, El-Mayta R, Metzloff AE, Billingsley MM, Hamilton AG, Mitchell MJ. In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity. Nat Mater. 2023 12; 22(12):1571-1580.
Score: 0.153
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|